share_log

Private Equity Firms Among Ocumension Therapeutics' (HKG:1477) Largest Stockholders and Were Hit After Last Week's 9.5% Price Drop

Private Equity Firms Among Ocumension Therapeutics' (HKG:1477) Largest Stockholders and Were Hit After Last Week's 9.5% Price Drop

私募股权公司是Ocumension Therapeutics(HKG: 1477)的最大股东之一,在上周股价下跌9.5%后受到打击
Simply Wall St ·  01/20 19:53

Key Insights

关键见解

  • Significant control over Ocumension Therapeutics by private equity firms implies that the general public has more power to influence management and governance-related decisions
  • A total of 4 investors have a majority stake in the company with 55% ownership
  • Insider ownership in Ocumension Therapeutics is 18%
  • 私募股权公司对Ocumension Therapeutics的严格控制意味着公众拥有更大的影响管理和治理相关决策的权力
  • 共有4名投资者拥有该公司的多数股权,拥有55%的所有权
  • Ocumension Therapeutics的内部所有权为18%

A look at the shareholders of Ocumension Therapeutics (HKG:1477) can tell us which group is most powerful. With 43% stake, private equity firms possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk).

看看Ocumension Therapeutics(HKG: 1477)的股东可以告诉我们哪个集团最强大。私募股权公司拥有43%的股份,是该公司的最大股份。换句话说,该集团面临最大的上行潜力(或下行风险)。

And following last week's 9.5% decline in share price, private equity firms suffered the most losses.

继上周股价下跌9.5%之后,私募股权公司遭受的损失最大。

Let's take a closer look to see what the different types of shareholders can tell us about Ocumension Therapeutics.

让我们仔细看看不同类型的股东能告诉我们关于Ocumension Therapeutics的哪些信息。

Check out our latest analysis for Ocumension Therapeutics

查看我们对Ocumension Therapeutics的最新分析

ownership-breakdown
SEHK:1477 Ownership Breakdown January 21st 2024
SEHK: 1477 所有权明细 2024 年 1 月 21 日

What Does The Institutional Ownership Tell Us About Ocumension Therapeutics?

关于Ocumension Therapeutics,机构所有权告诉我们什么?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

机构投资者通常将自己的回报与常见指数的回报进行比较。因此,他们通常会考虑收购相关基准指数中包含的大型公司。

As you can see, institutional investors have a fair amount of stake in Ocumension Therapeutics. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Ocumension Therapeutics' historic earnings and revenue below, but keep in mind there's always more to the story.

如你所见,机构投资者持有Ocumension Therapeutics的大量股份。这意味着在这些机构工作的分析师已经看过这只股票,他们很喜欢。但是就像其他人一样,他们可能错了。当多家机构拥有一只股票时,总是存在处于 “拥挤交易” 的风险。当这样的交易出错时,多方可能会竞相快速出售股票。对于没有增长历史的公司,这种风险更高。你可以在下面看到Ocumension Therapeutics的历史收益和收入,但请记住,故事总是有更多内容。

earnings-and-revenue-growth
SEHK:1477 Earnings and Revenue Growth January 21st 2024
SEHK: 1477 2024年1月21日收益及收入增长

We note that hedge funds don't have a meaningful investment in Ocumension Therapeutics. 6 Dimensions Capital, L.P. is currently the company's largest shareholder with 24% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 13% and 11%, of the shares outstanding, respectively. In addition, we found that Ye Liu, the CEO has 4.4% of the shares allocated to their name.

我们注意到,对冲基金没有对Ocumension Therapeutics进行有意义的投资。6 Dimensions Capital, L.P. 目前是该公司的最大股东,已发行股份为24%。同时,第二和第三大股东分别持有已发行股份的13%和11%。此外,我们发现首席执行官刘野以其名义分配了4.4%的股份。

To make our study more interesting, we found that the top 4 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.

为了使我们的研究更有趣,我们发现前四名股东控制着公司一半以上的股份,这意味着该集团对公司的决策具有相当大的影响力。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

虽然研究公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向哪个方向吹来也是有意义的。有相当数量的分析师在报道该股,因此了解他们对未来的总体看法可能很有用。

Insider Ownership Of Ocumension Therapeutics

Ocumension Therapeutics的内部所有权

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

公司内部人员的定义可能是主观的,并且在不同的司法管辖区之间确实有所不同。我们的数据反映了个人内部人士,至少涵盖了董事会成员。管理层最终对董事会负责。但是,经理成为执行委员会成员的情况并不少见,尤其是当他们是创始人或首席执行官时。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多数人认为内部所有权是积极的,因为这可能表明董事会与其他股东关系良好。但是,在某些情况下,过多的权力集中在该群体中。

It seems insiders own a significant proportion of Ocumension Therapeutics. Insiders have a HK$685m stake in this HK$3.9b business. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.

内部人士似乎拥有Ocumension Therapeutics的很大一部分股份。内部人士在这项39亿港元的业务中持有6.85亿港元的股份。很高兴看到内部人士对这项业务进行如此投资。可能值得检查一下这些内部人士最近是否在买入。

General Public Ownership

一般公有制

With a 28% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Ocumension Therapeutics. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Ocumension Therapeutics拥有28%的所有权,主要由个人投资者组成的公众对Ocumension Therapeutics有一定程度的影响力。这种所有权规模虽然可观,但如果决策与其他大股东不同步,可能不足以改变公司政策。

Private Equity Ownership

私募股权所有权

With an ownership of 43%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

私募股权公司拥有43%的所有权,有能力在制定以价值创造为重点的公司战略方面发挥作用。有些人可能会喜欢这样,因为私募股权有时是追究管理层责任的激进分子。但是其他时候,私募股权在公司上市后正在售罄。

Next Steps:

后续步骤:

It's always worth thinking about the different groups who own shares in a company. But to understand Ocumension Therapeutics better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Ocumension Therapeutics , and understanding them should be part of your investment process.

拥有公司股份的不同群体总是值得考虑的。但是,为了更好地了解Ocumension Therapeutics,我们需要考虑许多其他因素。例如,投资风险的幽灵无处不在。我们已经在Ocumension Therapeutics发现了一个警告信号,我们知道它们应该是你投资过程的一部分。

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

归根结底,未来是最重要的。您可以访问这份关于公司分析师预测的免费报告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发